Wells Fargo
ZNTL icon

Wells Fargo’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Wells Fargo’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Buy
41,898
+41,897
+4,189,700% +$167K ﹤0.01% 5200
2026
Q1 		$1 Buy
+1
New +$3 ﹤0.01% 7155
2025
Q3 		– Sell
-2,278
Closed -$2.64K – 7446
2025
Q2 		$2.64K Sell
2,278
-33,089
-94% -$43.6K ﹤0.01% 6178
2025
Q1 		$56.2K Buy
35,367
+758
+2% +$1.64K ﹤0.01% 5359
2024
Q4 		$105K Buy
34,609
+7,305
+27% +$23.9K ﹤0.01% 5182
2024
Q3 		$100K Sell
27,304
-772
-3% -$2.81K ﹤0.01% 5022
2024
Q2 		$115K Buy
28,076
+7,995
+40% +$89.3K ﹤0.01% 4851
2024
Q1 		$316K Buy
20,081
+1,635
+9% +$22.5K ﹤0.01% 4186
2023
Q4 		$279K Sell
18,446
-31,835
-63% -$464K ﹤0.01% 4257
2023
Q3 		$1.01M Sell
50,281
-15,020
-23% -$381K ﹤0.01% 3323
2023
Q2 		$1.84M Buy
65,301
+18,544
+40% +$445K ﹤0.01% 2982
2023
Q1 		$804K Buy
46,757
+43,621
+1,391% +$883K ﹤0.01% 3535
2022
Q4 		$63.2K Sell
3,136
-2,533
-45% -$54.5K ﹤0.01% 4760
2022
Q3 		$122K Sell
5,669
-40,814
-88% -$1.12M ﹤0.01% 4507
2022
Q2 		$1.31M Sell
46,483
-81,935
-64% -$2.17M ﹤0.01% 3118
2022
Q1 		$5.92M Sell
128,418
-1,562
-1% -$84.3K ﹤0.01% 2303
2021
Q4 		$10.9M Sell
129,980
-365,751
-74% -$28.3M ﹤0.01% 1793
2021
Q3 		$33M Sell
495,731
-11,465
-2% -$661K 0.01% 1314
2021
Q2 		$27M Buy
507,196
+503,339
+13,050% +$27M 0.01% 1455
2021
Q1 		$167K Sell
3,857
-13,008
-77% -$560K ﹤0.01% 5240
2020
Q4 		$876K Buy
16,865
+8,415
+100% +$380K ﹤0.01% 4127
2020
Q3 		$276K Buy
8,450
+3,205
+61% +$112K ﹤0.01% 4774
2020
Q2 		$252K Buy
+5,245
New +$201K ﹤0.01% 4774

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Wells Fargo's ZNTL Position: Q2 2026 in Review

Wells Fargo increased its Zentalis Pharmaceuticals (ZNTL) stake by 4,189,700% in Q2 2026, buying an estimated $167K and bringing the position to 41,898 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #5200.

Wells Fargo first reported a position in ZNTL in Q2 2020 and has held it in 23 quarters since. The position peaked at $33M in Q3 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Wells Fargo held 41,898 shares of Zentalis Pharmaceuticals worth $203K as of Q2 2026.
  • Wells Fargo bought 41,897 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $167K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5200 holding.
  • Wells Fargo first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Wells Fargo's Zentalis Pharmaceuticals position peaked at $33M in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.